Evidence map›Paper›PMID 40698031›Full record

ArticleOpen forum infectious diseases2025

Types of Myocardial Infarction in People With HIV in Switzerland.

Julia N Kleynhans, Naomi N Cobo, Emma F Avery, Ronny R Buechel, Christian W Thorball, Isabella C Schoepf, Tania Coscia, Dominique L Braun, Eugénie Colin-Benoit, Catia Marzolini and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Julia N KleynhansUniversity Center for Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel  Bruderholz, Switzerland.ORCID https://orcid.org/0009-0003-5508-8951
Naomi N CoboUniversity Center for Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel  Bruderholz, Switzerland.ORCID https://orcid.org/0009-0009-0307-0139
Emma F AveryUniversity Center for Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel  Bruderholz, Switzerland.ORCID https://orcid.org/0009-0001-5367-1313
Ronny R BuechelDepartment of Nuclear Medicine, Cardiac Imaging, University and University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-8064-8904
Christian W ThorballPrecision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-6869-6943
Isabella C SchoepfUniversity Center for Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel  Bruderholz, Switzerland.ORCID https://orcid.org/0000-0003-0882-8016
Tania CosciaCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Dominique L BraunDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-4036-1030
Eugénie Colin-BenoitDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-6327-1949
Catia MarzoliniDivision of Infectious Diseases, Basel University Hospital, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-2312-7050
Christian R KahlertDepartment of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, St. Gallen, Switzerland.ORCID https://orcid.org/0000-0002-0784-3276
Enos BernasconiDivision of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and Università Della Svizzera Italiana, Lugano, Switzerland.ORCID https://orcid.org/0000-0002-9724-8373
Matthias CavassiniInfectious Diseases Service, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-0933-7833
Annalisa MarinosciDivision of Infectious Disease, Geneva University Hospital, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-8054-0044
Katharina KusejkoDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-4638-1940
Jacques FellayPrecision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-8240-939X
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1142-6723
Bruno LedergerberDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-6881-4401
Philip E TarrUniversity Center for Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel  Bruderholz, Switzerland.ORCID https://orcid.org/0000-0002-1488-5407
Swiss HIV Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Of myocardial infarctions (MIs) recorded in 2 large human immunodeficiency virus (HIV) observational studies from North America, approximately half were classified as type 2. In the REPRIEVE clinical trial of pitavastatin versus placebo in people with HIV (PWH) (<3% of participants were from Europe), 20.6% of MIs were type 2. The proportions of type 1 MI (T1MI) and type 2 MI (T2MI) in European PWH are unknown. Methods: The study included a retrospective record review, ascertainment of prospectively recorded and medically validated MIs, differentiation of T1MI and T2MI, and MI time trend analysis in the Swiss HIV Cohort Study (1 January 2000 to 31 May 2021). Exploratory analysis was performed of the associations of T1MI and T2MI with blood leukocyte count and 2 validated genome-wide coronary artery disease-associated polygenic risk scores (metaGRS and GPS Results: Between 2000 and 2021, 16 027 Swiss HIV Cohort Study participants accumulated 181 598 years of follow-up, and 379 had a validated first MI. Of these participants, 359 (94.7%) had T1MI, and 20 (5.3%) had T2MI. Invasive coronary angiography was done in 95% and 60% of participants with T1MI and T2MI, respectively. We found no evidence for increasing or decreasing incidence trends over time for T1MI ( Conclusions: The proportion of T2MI in PWH in Switzerland is approximately 5%, consistent with data from the general population and lower than in previous North American reports among PWH.

Indexed as

HIV infectionmyocardial infarctiontime trendstype 1 myocardial infarctiontype 2 myocardial infarction

Identifiers

PMID40698031
PMCPMC12282347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.